Literature DB >> 20865848

Urticarial hypersensitivity reaction caused by temozolomide.

Salma Pothiawala1, Mei-Yu Hsu, Clarissa Yang, Santosh Kesari, Omar A Ibrahimi.   

Abstract

Temozolomide is an oral alkylating agent approved for the treatment of glioblastoma and anaplastic astrocytoma, and is currently under clinical investigation for the treatment of brain metastases from a variety of cancers. Temozolomide is well tolerated, and the reported dermatologic side effects of this medication are limited. Here, the authors report the first case of an urticarial hypersensitivity reaction induced by temozolomide. As this drug will likely be increasingly utilized in the near future, it is important to be aware of its potential to cause adverse cutaneous manifestations.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20865848

Source DB:  PubMed          Journal:  J Drugs Dermatol        ISSN: 1545-9616            Impact factor:   2.114


  2 in total

1.  Two cases of cutaneous drug eruption associated with temozolomide therapy for glioblastoma.

Authors:  E Deluche; S Leobon; F Touraine; P Clavère
Journal:  Curr Oncol       Date:  2014-12       Impact factor: 3.677

2.  Cutaneous adverse drug reaction associated with oral temozolomide presenting as dermal and subcutaneous plaques and nodules.

Authors:  Pooja Virmani; Esther Chung; Alissa A Thomas; Ingo K Mellinghoff; Michael A Marchetti
Journal:  JAAD Case Rep       Date:  2015-07-29
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.